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INTRODUCTION
Gag capsid (CA) protein, a major virion component of all retrovi-
ruses including human and simian immunodeficiency viruses (HIV/
SIVs), plays an essential role for virus life cycle at both early and late
replication phases (1-3). HIV-1 Gag is intracellularly synthesized
as a precursor, and subsequently cleaved into matrix (MA), CA,
nucleocapsid (NC), and p6 as functional mature products during
the virion maturation process (2, 4 -7). The CA N-terminal domain
(NTD) of HIV-1 are composed of N-terminal β -hairpin, seven α -
helices, and loop structures, and constitutes the exposed outer sur-
face. Indeed, CA-NTD is known to interact with various cellular
factors that regulate virus replication (2, 6-8). Of note, macaque α -
isoform of tripartite motif -containing protein 5 (TRIM5α) and re-
lated proteins, major cellular determinants for HIV-1 species tro-
pism, eliminate HIV-1 infectivity by binding to its CA-NTD and by
aberrantly promoting the post-entry disassembly process of CA (9,
10).
To clarify the functional details of HIV-1 Gag-CA, its biological
and biochemical properties have been extensively analyzed by nu-
merous mutational studies until now (reference 11 as representa-
tive). In those works on Gag-CA, deletion, insertion, proline-scan-
ning, and/or alanine-scanning mutations were introduced into the
amino acid residues conserved among HIV-1/SIV strains, and re-
sultant mutants were examined for their viral phenotypes. In this
study, we have adopted a different strategy to construct test mu-
tants hoping to identify potential new CA activities. Eighteen amino
acids specific to HIV-1 in the sequence alignment of HIV-1 (NL4-
3), HIV-2 (GL-AN), and SIVmac (MA239) were replaced with
those of SIVmac at the corresponding sites to generate HIV-1 CA
mutants. In addition, a mutant I134Q was constructed, considering
that there are two consecutive isoleucine residues at amino acid
positions 134 and 135 in the NL4-3 sequence, and also that there is a
glutamine residue at position 135 conserved in the sequences of GL-
AN and MA239. To increase chances to obtain new findings, we
have focused on the CA-NTD region here because (i) CA-NTD is
more heterologous than CA C-terminal domain (CTD) with re-
spect to the amino acid sequence, and (ii) various interactions be-
tween CA-NTD and cellular factors have been documented to date.
Totally, nineteen site -specific point mutants of HIV-1 CA-NTD
were generated, and were characterized for basic viral pheno-
types, i.e., virus growth potential, early post-entry infectivity, and
virion production level at final replication phase, in this study.
MATERIALS AND METHODS
Construction of proviral mutant clones
Four infectious molecularclones designated NL4-3(HIV-1), GL-
AN (HIV-2), MA239 (SIVmac239, virus clone from a rhesus ma-
caque (mac)), and NL-DT5R (macaque-tropic HIV-1) have been
previously described (12-16). Proviral CA-NTD mutant clones de-
rived from HIV-1 NL4-3 and NL-DT5R in this study were gener-
ated by the QuickChange site -directed mutagenesis kit (Agilent
Technologies Inc) as previously described (17-19). Nucleotide se-
quences of the mutant clones were confirmed by ABI Genetic
Analyzer 3130xl (Thermo Fisher Scientific).
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Cells
A human kidney cell line 293T and a HeLa-derived reporter cell
line TZM-bl carrying a luciferase gene under control of HIV-1 long
terminal repeat (LTR) were cultured in Eagle’s minimal essential
containing 10% heat- inactivated fetal bovine serum (20). Lympho-
cyte cell lines H9 (human) and HSC-F (cynomolgus macaque)
were maintained in RPMI1640 medium containing 10% heat- inac-
tivated fetal bovine serum(19, 21).
Transfection
Input viruses for infection experiments were prepared from 293T
cells transfected with various proviral clones by the calcium-pho-
sphate co-precipitation method (12, 17). Virus amounts were de-
termined by virion-associated reverse transcriptase (RT) assays as
previously described (17, 22). To determine the virus production
level in lymphocyte cells, proviral clones (2 μg) and pGL3 (lu-
ciferase reporter vector) (2 μg) were cotransfected into H9 cells by
Nucleofectorusing program X-005 and Nucleofector kit V
(Lonza Ltd.). H9 cells were then cultured in the presence of AMD
3100 (antagonist against CXCR4-tropic HIV-1) that prevents the re-
infection of cells with progeny viruses produced by transfection.
On day 2 post- transfection, culture supernatants were collected,
and virion production was monitored by HIV-1 Gag-p24 ELISA kit
(ZeptoMetrix Corporation). Virion production level in H9 cells
cannot be determined by the RT assay due to its relatively low
sensitivity. Luciferase activity in cell lysates was used to normalize
the transfection efficiency.
Assays for viral infectivity
To monitor multi -cycle infectivity (virus growth ability/poten-
tial), equal RT units (105 for H9 cells and 106 for HSC-F cells) of
virus samples were infected into H9 (105) or HSC-F cells (2 x 105),
and virus growth kinetics were determined by RT assays as previ-
ously described (17, 20). H9 and HSC-F cell lines show phenotypes
very similar to that of their corresponding primary cells such as
peripheral blood mononuclear cells and lymphocytes with respect
to the susceptibility to infections with various HIV/SIVs and/or
their mutant viruses. Progeny viruses produced in infected cells
were monitored at intervals (every 3 days) during 15 days following
infection. To determine single-cycle infectivity, equal RT units
(104) of virus samples were inoculated into TZM-bl cells (4 x 103
cells were seeded into a well of a 96-well plate one day before
infection), and on day 1 post- infection, cells were lysed for lu-
ciferase assays (Promega Corporation) as described previously
(20). Luciferase activity in cell lysates relative to that of NL4-3 was
considered as viral single-cycle infectivity. This infectivity repre-
sents “viral infectivity at the early replication phase”, because the
luciferase activity in TZM-bl cells is induced by viral early protein
Tat through the transcriptional activation.
RESULTS
Generation of HIV-1 CA-NTD mutants
HIV-1 Gag-CA consists of two independent domains NTD and
CTD connected by a flexible linker region (Fig. 1). There are a β -
hairpin and seven helical structures in CA-NTD, whereas four
Figure 1 Alignment of Gag-CA NTD sequences. Amino acid sequences of HIV-1 NL4-3 (GenBank accession number : AF324493), HIV-2 GL-AN
(GenBank accession number : M30895), and SIVmac MA239 (GenBank Accession number : M33262) CA-NTD proteins are comparatively pre-
sented. Structural domains/regions are indicated above (helices) or below (linker domain and major homology region (MHR)) the sequence
alignment. HIV-1 CA-NTD is from the N-terminus to the end of helix 7, and CA-CTD is from I150 or L151 to the C-terminus (34). Amino acid sites for
mutational analysis in this study are represented by red letters.
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helices in CA-CTD. Although these structural characteristics are
conserved, amino acid sequences in Gag-CA are quite different
between viruses of HIV-1 and HIV-2/SIVmac groups. According
to Genetyx version 11, as for CA-NTD amino acid sequences, 62%
identity (85% similarity) for NL4-3 (HIV-1) vs. GL-AN (HIV-2),
62% identity (86% similarity) for NL4-3 vs. MA239 (SIVmac), and
85% identity (97% similarity) for GL-AN vs. MA239. RegardingCA-
CTD amino acid sequences, 74% identity (97% similarity) for NL4-3
vs. GL-AN, 74% identity (97% similarity) for NL4-3 vs. MA239, and
98% identity (100% similarity) for GL-AN vs. MA239. Thus, CA-
CTD is more conserved than CA-NTD in terms of amino acid se-
quences, and is almost indistinguishable between GL-AN and MA
239.
Based on the above consideration, we constructed a new series of
CA-NTD mutants in a unique way, i.e., introduction of mutations
into non-conserved amino acids as indicated in Fig. 1, to obtain
potentially useful information for future studies. Exceptionally, we
constructed a mutant I134Q side by side with the I135Q mutant
(Fig. 1). We mainly introduced mutations into helical domains. It is
already known that the loop structure between helices 4 and 5 (4-5
loop) serves as binding site for cellular proline isomerase cyclo-
philin A, regulating viral replication (2, 7, 8). The 4-5 and 6-7
loops in CA-NTD are shown to be critical by us for human specific
nature of HIV-1 as viral determinants for narrow HIV-1 species
tropism (16, 23). Moreover, amino acid mutations M94L and
R98S in 4-5 loop and G114Q in helix 6 were demonstrated also
by us to be important for the species tropism (17). On balance,
as summarized in Table 1, we finally constructed 19 proviral mu-
tants carrying a site -specific point mutation in CA-NTD.
Virological characterization of HIV-1 CA-NTD mutants
Various HIV-1 clones carrying a site -specific mutation in CA-
NTD (Fig. 1 and Table 1) were analyzed for their viral properties by
transfection and infection experiments. First, each mutant virus
was examined for its ability to grow in H9 cells. Input viruses for
infection prepared from transfected 293T cells were inoculated into
target H9 cells, and virus growth properties were determined by
RT assays. Representative results are shown in Fig. 2, and all the
data obtained were summarized in Table 1. Based upon growth
potentials in a lymphocyte cell line H9, mutant virus clones can be
classified into four groups as readily recognizable in Fig. 2 : i)
clones with a similar growth ability to parent NL4-3 (E79D and R
100S) ; ii) clone with a poor growth ability relative to NL4-3 (E71
D) ; iii) clone with a severely impaired growth ability (Q112D) ; iv)
clone with undetectable growth ability (T119Y). Another important
point to be mentioned here is that all helix 7 mutants lost infec-
tivity as a result of the point mutation (Table 1). This is in con-
trast with the helix 4 mutants, which showed various growth
phenotypes (from i) to iv)) as described above.
Next, in order to infer defective sites of non- infectious mu-
tants in H9 cells (12 mutants in Table 1), single-cycle replication
assays, i.e., TZM-bl and virion production assays, were performed
to examine their early and late replication phases. Upon transfec-
tion into 293T cells, these mutants did produce virions, albeit to
various degrees, as monitored by RT assays. Fig. 3 shows the early
infectivity of the mutants derived from transfected 293T cells rela-
tive to that of NL4-3 as determined by TZM-bl assays. It is clearly
observed that all the mutants examined exhibit significantly low
infectivity compared to NL4-3. Particularly, the infectivity of
A31K, Q50Y, K70R, R82L, T119Y, E128N, and I134Q was ex-
tremely low or even undetectable, indicating the functional impor-
tance of the authentic amino acids at early replication phase. Ex-
amination of the late replication phase by virion production in
transfected H9 cells (Fig. 4) revealed that the non- infectious mu-
tants tested were generally not so much defective as observed in
Fig. 3. Of note, although data fluctuations were somewhat large,
mutations in the 1-2 loop and helices 2/3 (A31K, S41Q, and Q50Y)
did not affect much the late replication phase (compare the average
values obtained for the three mutants and the others in Fig. 4).
Because transfected 293T cells could produce virions at a consider-
able level as judged by RT assays as described above, the negative
results for K70R and I134Q (perhaps for I135Q also) in Fig. 4
probably came from the inability of the anti -Gag-p24 (CA) anti-
bodies in the ELISA kit to detect the mutant CA proteins. Table 1
summarizes all the quantitative data obtained for the early and late
replication efficiencies of the mutants (Figs. 3 and 4).
Finally, the helix 7 mutants (I134Q and I135Q) were evaluated
for their replication potentials in macaque cells. Based on striking
results on the helix 7 mutants that none were infectious for H9
cells, we speculated that authentic amino acids there are somehow
involved in the narrow host range of HIV-1. We generated mu-
tants in a virus- lineage reflected way (Fig. 1), and could assume
that there were some amino acids and/or regions in CA-NTD rele-
vant to or responsible for efficient HIV-1 replication only in human
cells. To test this hypothesis, I134Q and I135Q mutations were indi-
vidually introduced into a macaque cell - tropic NL-DT5R clone
(16). Input viruses were then prepared from 293T cells transfected
with test samples or negative (NL4-3) and positive (NL-DT5R)
control clones, and inoculated into cynomolgus macaque HSC-F
cells (21). As clearly seen in Fig. 5, while NL4-3 did not grow at all in
HSC-F cells, NL-DT5R grew well with a peak on day 9. No virus
replication was detected during 15 days observation period for the
two mutants of duplicate samples.
Table 1 Virological characteristics of CA-NTD mutants in this study
Parent and
mutant clones
Mutated
domain
Virus
growth
in H9 cells
Infectivity in
TZM-bl cells
Virion
production
in H9 cells
NL4-3 None +++ 1.000.00 1.000.00
A31K H1/2  0.010.00 0.860.33
S41Q Helix 2  0.190.04 1.040.36
Q50Y Helix 3  0.060.01 0.930.24
T58C H3/4 + ND ND
K70R Helix 4  0.040.02 NA
E71D Helix 4 ++ ND ND
T72I Helix 4 + ND ND
E79D Helix 4 +++ ND ND
R82L Helix 4  0.010.01 0.350.09
L83Q Helix 4 + ND ND
R100S H4/5 +++ ND ND
Q112D Helix 6 + ND ND
T119Y Helix 6  0.030.01 0.310.05
E128N Helix 7  0.020.01 0.390.09
K131R Helix 7  0.380.11 0.460.08
I134Q Helix 7  0.000.00 NA
I135Q Helix 7  0.120.04 0.090.07
N139Q Helix 7  0.340.12 0.460.16
I141C Helix 7  0.120.04 0.370.08
Parent and mutant clones : Bold letters indicate the mutant clones that lack
growth ability in H9 cells.
Mutated domain : H1/2, between helices 1 and 2 ; H3/4, between helices 3
and 4 ; H4/5, between helices 4 and 5. See Fig. 1 for details.
Virus growth :, no growth ;+, severely retarded growth (see Q112D in
Fig. 2) ;++, retarded growth (see E71D in Fig. 2) ;+++, similar growth
with NL4-3.
Infectivity : ND, not determined.
Virion production : ND, not determined ; NA, not applicable (see text for
details).
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DISCUSSION
In this study, we have performed a systemic mutational analysis
on HIV-1 CA-NTD (145 amino acids), and provide basic informa-
tion on virological properties of the mutants with a site -specific
point mutation throughout the domain (Table 1). Using a unique
virus- lineage dependent mutagenesis, we totally constructed 19
mutants, and 12 mutants were found to be non- infectious for a
human lymphocyte cell line H9. All the non- infectious mutants
were defective at the early replication phase (A31K, S41Q, Q50Y,
K70R, R82L, T119Y, E128, K131R, I134Q, I135Q, N139Q, and I141C),
whereas three were certainly not defective at thelate phase (A31K,
S41Q, and Q50Y). Our results presented here are generally consis-
tent with those previously reported (11). Of particular interest in
this study is the unexceptional lethal effect by mutations in CA-
NTD helix 7 (E128N, K131R, I134Q, I135Q, N139Q, and I141C).
HIV-1 Gag-CA is involved in a series of different interactions in
the processes of viral core disassembly at the post-entry early
Figure 2 Growth kinetics in human H9 cells of CA-NTD mutants
derived from HIV-1 NL4-3. Viruses were prepared from 293T cells trans-
fected with proviral clones indicated, and equal amounts (105 RT units)
were inoculated into H9 cells (105). RT activity in the culture supernatants
was determined every 3 days up to 15 days post - infection. The experi-
ment was repeated with similar results.
Figure 3 Single -cycle infectivity in TZM-bl cells of CA-NTD mutants
derived from HIV-1 NL4-3. Viruses were prepared from 293T cells trans-
fected with proviral clones indicated, and equal amounts (104 RT units)
were inoculated into sub-confluent TZM-bl cells in wells of a 96 -well
plate. On day 1 post - infection, cells were lysed for luciferase assays.
Infectivity of each mutant relative to that of NL4-3 is shown. Mean
valuesSD from at least three independent experiments are presented.
Significance relative to NL4-3 was determined by the Student t test
(**, p0.01 ; *, p0.05).
Figure 4 Ability of CA-NTD mutants derived from HIV-1 NL4-3 to
produce progeny virions in H9 cells. Proviral clones indicated (2 μg) and
pGL3 (luciferase reporter vector) (2 μg) were co-nucleofected into H9
cells, and on day 2 post - transfection, culture supernatants were prepared
for Gag-p24 ELISA assays. Gag-p24 production by each mutant rela-
tive to that by NL4-3 is shown. Luciferase activity in cell lysates was
used for normalization of the transfection efficiency. Mean valuesSD
from at least three independent experiments are presented. Signifi-
cance relative to NL4-3 was determined by the Student t test (**, p
0.01 ; *, p0.05).
Figure 5 Growth in cynomolgus HSC-F cells of I134Q and I135Q
mutants derived from macaque cell - tropic HIV-1 NL-DT5R. Viruses
were prepared from 293T cells transfected with proviral clones indicated,
and equal amounts (106 RT units) were inoculated into HSC-F cells (2 x
105). RT activity in the culture supernatants was determined every 3
days up to 15 days post - infection. The infection experiment for the mu-
tants was performed in duplicate using independently prepared virus
samples (both DNA preparation for transfection and virus preparation
from transfection were independently carried out). 5R, NL-DT5R (16).
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replication phase, and virion assembly and maturation at the late
final replication phase (2-8). It is mainly composed of helical domains
NTD and CTD, and while NTD primarily forms a hexameric/pen-
tameric structures, CTD interacts with the NTD of adjoining CA
molecules (4-7). Although it has been well demonstrated structur-
ally and functionally that amino acids in NTD helices 1-6 are impor-
tant for core formation, Gag assembly, and virion production (11,
24, 25), structural and functional roles of the helix 7 in these proc-
esses are poorly understood as yet. Considering that all the non-
infectious CA-NTD mutants including those of the helix 7 in this
study are defective for the early replication phase (Table 1), it is
pivotal to determine the underlying molecular basis. It is also
necessary to define in detail how virion-Gag disassembles at the
early post-entry stage. This subject is now under vigorous investi-
gation by many researchers (26-31). For better understanding
the HIV-1 virology and for therapeutic purpose, the above issues
need to be precisely elucidated.
HIV-1 is believed to have evolved to its present form as a human
specific pathogen following numerous mutations, recombinations,
and adaptations from the ancestral virus(es) (32). Most evident
virological property of HIV-1 is that it grows well almost exclu-
sively in human cells and individuals. The determinants for this
narrow host range are CA-NTD and Vif as demonstrated by us and
others (16, 17, 33). Some amino acids responsible for the tropism
are identified in CA-NTD as described above (16, 17). When se-
lecting the target amino acids for mutation analysis in this study, we
assumed a possibility that some, non-conserved among HIV-1,
HIV-2, and SIVmac, might contribute to theefficient HIV-1 replica-
tion in human cells. We therefore introduced two mutations in
helix 7 into macaque-tropic HIV-1 NL-DT5R, and verified the possi-
bility by infecting macaque HSC-F cells with mutant NL-DT5R
viruses. Although not completely excluded, our hypothesis is now
unlikely from the results in Fig. 5. Further study is required to
identify amino acids and/or regions relevant to or account for the
efficient replication of HIV-1 specifically in human cells, if any.
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